On the afternoon of March 28, the representatives of Consulate General of the Kingdom of Belgium in Guangzhou visited Guangzhou, aiming to promote mutual understanding of the business environment and discuss opportunities for exchanges and cooperation between the two sides.
It is known that Belgium has the following outstanding advantages in the fields of biotechnology and life sciences, in addition to its superior geographical location and good investment policy environment:
Strong R&D capability
Belgium has 16 universities, 22 research institutes and 25 science and technology parks.
Belgium's pharmaceutical industry has the fastest speed in Europe from R&D to production. It is a country with the highest per capita clinical trials in the world and its number of clinical trials ranks the second in Europe. The time of approval of clinical trials only takes 28 days. Patent issuance takes only 18 months, and under the same conditions, only half of the time in Britain, France and other countries.
Government Incentive Policies
R&D personnel working in Belgium receive 65% of the personal income tax rebate and 80% of the tax exemption for specific patent income (the same applies to branches established by foreign enterprises in Belgium).
Biowin, a biotechnology and health industry cluster in Walloon, and Wallonie will provide 60% to 70% of the special subsidies for enterprises engaged in biotechnology research and development.
As a result, Belgium has attracted 720 multinational biopharmaceutical companies including Pfizer, GlaxoSmithKline, Janssen, UCB and many other well-known global brands to settle down there.
Some reference materials:
1. China-Belgium Science and Technology Park (CBTC) – a China-Europe Platform for Innovation and Cooperation in Biotechnology Industry, Xinye News Agency
2. Belgium Investment Environment Analysis and Prospect Forecast Report, CIC Consultant, CIC Industry Research Press, 2019-2023
3. Encyclopedia, Belgium
The above part is extracted from the reference materials, which does not represent the views and positions of ICAP. If there is any infringement, please send relevant proof materials to email@example.com, and we will help contact the original author for processing. In no event shall the information contained herein or the opinions expressed herein represent advertising, offers, invitations to offer, or investment advice to any person.
ICAP Small Round Table Interaction Series in emerging industries (hereinafter referred to as ICAP Small Round Table) serves as a platform for in-depth dialogue, exchange and cooperation among government authorities, scientific research institutions, enterprises, scientists, investment institutions and media of emerging industries in various countries and regions around the world, which is built by ICPA in accordance with the corporate purpose of being a service providers for the emerging industries.
Infinite Capital Holding Company (ICAP) is an enterprise organized by Guangzhou Municipal Government, and composed of 53 publically traded A-share listed companies in China including Wondfo, Hybio, Blueon, and Shangpin Home Collection. The shareholders are mainly from emerging industries in the field of bioscience, artificial intelligence and information technology.
The mission of ICAP is to be an emerging industrial service provider.
The business model of ICAP is to cooperate with listed companies in emerging industries to jointly invest in international emerging industries technology.
The business model of ICAP includes international technology investment bank, new industrial park and emerging industry fund.